IRCT20210214050350N1招募中3 期
Comparing the effectiveness of Lopinavir/Ritonavir/Hydroxychloroquine and Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine treatment regiments in moderate to severe COVID-19 patients
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- no limit 至 no limit（—）
- 性别
- All
入选标准
- •Having three or more of the following conditions:(1) Cough (2) weakness (3) fever of =38.5°C (4) Intense fatigue (5) myalgia (6) sore throat (7) Dyspnea (8) Low appetite/Diarrhea/nausea (9) Decreased awareness
- •Or having one or more of the following disease characteristics: (1) Oxygen saturation value of less than 93% (2) disease confirmation based on chest imaging results (3) A respiratory rate greater than 24 breaths per minute
排除标准
- •Negative COVID-19 specific PCR test result
- •Patients that are well enough to not need hospitalization
研究者
相似试验
招募中
不适用
The pharmacokinetics of lopinavir/ritonavir, nevirapine and efavirenz when given with isoniazid in South African HIV-infected individualsHIV/AIDSTuberculosisPACTR201206000391313niversity of Cape Town70
进行中（未招募）
1 期
Efficacy of Switching to Lopinavir/Ritonavir (Kaletra) in Improving Cognitive function in patients treated with Efavirenz (EFV) (SLICE Study)EUCTR2011-005581-37-GBThe Newcastle upon Tyne Hospitals NHS Foundation Trust16
进行中（未招募）
1 期
A Randomized, Open-label, Study of Lopinavir/ritonavir 400/100 mg Tablet Twice-Daily + Co-formulated Emtricitabine/Tenofovir Disoproxil Fumarate 200/300 mg Once-Daily Versus Lopinavir/ritonavir 400/100 mg Tablet Twice-Daily + Raltegravir 400 mg Twice-Daily in Antiretroviral-Naïve, HIV-1 Infected SubjectsEUCTR2008-000881-22-FRAbbott GmbH & Co. KG200
进行中（未招募）
不适用
A Randomized, Open-label, Study of Lopinavir/ritonavir 400/100 mg Tablet Twice-Daily + Co-formulated Emtricitabine/Tenofovir Disoproxil Fumarate 200/300 mg Once-Daily Versus Lopinavir/ritonavir 400/100 mg Tablet Twice-Daily + Raltegravir 400 mg Twice-Daily in Antiretroviral-Naïve, HIV-1 Infected SubjectsEstudio aleatorizado y abierto de 400/100 mg de lopinavir/ritonavir en comprimidos dos veces al día + coformulación de emtricitabina/tenofovir disoproxil fumarato, 200/300 mg una vez al día, frente a 400/100 mg de lopinavir/ritonavir en comprimidos dos veces al día + raltegravir, 400 mg dos veces al día, en sujetos infectados por el VIH-1 sin tratamiento antirretroviral previo.Treatment-naïve, HIV-1 infected subjectsSujetos infectados por el VIH-1 sin tratamiento antirretroviral previo.MedDRA version: 9.1Level: LLTClassification code 10020162Term: HIV infection CDC Group IEUCTR2008-000881-22-ESAbbott GmbH & Co. KG200
进行中（未招募）
不适用
A randomized, open-label, study of lopinavir/ritonavir 400/100 mg tablet twice-daily + co-formulated emtricitabine/tenofovir disoproxil fumarate 200/300 mg once-daily versus lopinavir/ritonavir 400/100 mg tablet twice-daily + raltegravir 400 mg twice-daily in antiretroviral-naive, HIV-1 infected subjects. - NDEUCTR2008-000881-22-ITAbbott GmbH & Co. KG200